Scientists find new drug targets in aggressive cancers

November 5, 2018, Dana-Farber Cancer Institute
cancer
Killer T cells surround a cancer cell. Credit: NIH

Scientists have discovered a previously unknown molecular vulnerability in two rare, aggressive, and hard-to-treat types of cancer, and say it may be possible to attack this weakness with targeted drugs.

Reporting in Nature Cell Biology, researchers at Dana-Farber Cancer Institute show that these two cancers—synovial sarcoma and malignant rhabdoid tumors—are dependent on a newly characterized "molecular machine" called ncBAF, which plays unique roles in regulating gene activity. The scientists showed that biologically and chemically disabling components of ncBAF—which is made up of several unique protein subunits—specifically impaired the proliferation of two types of cell lines which share a common disruption.

"This is one of the first suggestions toward a route for therapeutic intervention in these intractable, aggressive cancers," said Cigall Kadoch, Ph.D., of Dana-Farber Cancer Institute, senior author of the report in Nature Cell Biology. "These findings identify new, cancer-specific targets which may be extendable to other cancer types as well."

Synovial sarcoma is a rare cancer of soft tissues that typically is diagnosed in young adults. Malignant rhabdoid tumors are also rare but are very aggressive and usually develop in children under the age of two. They can affect the brain, kidney, and other organs.

Recent work by Kadoch's team as well as other groups has implicated these molecular machines, called chromatin-remodeling complexes, in the development and maintenance of cancer. These complexes are clusters of proteins that remodel the way the DNA in a cell is packaged—and in doing so, help regulate which genes are turned on and off. Each of the complexes is made up of numerous protein subunits.

Kadoch's research has focused on a category of chromatin remodeling complexes known as the SWI/SNF family. There are three types of complexes in the family—cBAF, PBAF, and ncBAF. Two weeks ago, in Cell, the Kadoch group reported the order of assembly and modular organization of these complexes for the first time. Importantly, these chromatin remodelers travel to various locations on the DNA genome within the cell and regulate which genes are turned on, and when, to generate the cell's proteins needed at various times. It's estimated that 20 percent of human cancers are associated with mutations in the genes that code for the chromatin-remodeling subunits, resulting in disruption of gene expression and leading to the development of tumors.

In the current study, the researchers report that the ncBAF complex (nc stands for non-canonical) differs from the other two complexes (cBAF and PBAF) in several ways, including where on the genome it acts. In addition, ncBAF is different because it contains two subunits, BRD9 and GLTSCR1, that aren't parts of any other complexes, and lacks subunits that are found in other complexes.

Most intriguingly—and relevant for cancer—the researchers found that ncBAF function is specifically required by synovial sarcoma and malignant rhabdoid tumors to maintain their cell division and growth. Owing to its dependence in these cancers, ncBAF is termed a "synthetic lethal target," suggesting that disrupting ncBAF could be a viable approach to treating these tumors.

Kadoch and her colleagues are particularly interested in the BRD9 subunit of the ncBAF complex, because there are existing small molecule probes that can block BRD9 activity, as well as experimental agents, known as protein degraders, that are designed to eliminate BRD9 from .

"This was an unexpected target, and these findings are already being explored pre-clinically" in hopes of treating the two rare cancers, Kadoch says. Co-first authors of the work are Brittany Michel, Andrew D'Avino, and Seth Cassel.

Explore further: For prostate cancer, study identifies how common mutation makes good cells go bad

More information: A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation, Nature Cell Biology (2018). DOI: 10.1038/s41556-018-0221-1 , https://www.nature.com/articles/s41556-018-0221-1

Related Stories

For prostate cancer, study identifies how common mutation makes good cells go bad

August 3, 2018
In more than half of all prostate tumors, two genes—one for a transcription factor called ERG, the other a testosterone-triggered gene called TMPRSS2—become fused together, resulting in excess ERG expression. The TMPRSS2-ERG ...

Protein complex may play role in preventing many forms of cancer, study shows

May 5, 2013
Researchers at the Stanford University School of Medicine have identified a group of proteins that are mutated in about one-fifth of all human cancers. The finding suggests that the proteins, which are members of a protein ...

Cancer gene dependency maps help reveal proteins' relationships

May 17, 2018
By merging cancer functional genetic data with information on protein interactions, scientists can explore protein complexes at massive scale.

Recommended for you

From the ashes of a failed pain drug, a new therapeutic path emerges

November 16, 2018
In 2013, renowned Boston Children's Hospital pain researcher Clifford Woolf, MB, BCh, Ph.D., and chemist Kai Johnsson, Ph.D., his fellow co-founder at Quartet Medicine, believed they held the key to non-narcotic pain relief. ...

Repurposing FDA-approved drugs can help fight back breast cancer

November 16, 2018
Screening Food and Drug Administration (FDA)-approved compounds for their ability to stop cancer growth in the lab led to the finding that the drug flunarizine can slow down the growth of triple-negative breast cancer in ...

Traditional chemotherapy superior to new alternative for oropharyngeal cancers

November 16, 2018
A drug increasingly used in combination with radiotherapy to treat a type of cancer that forms in the tonsils or the base of the tongue is inferior to a previously favored option, according to a large, clinical trial led ...

New 'SLICE' tool can massively expand immune system's cancer-fighting repertoire

November 15, 2018
Immunotherapy can cure some cancers that until fairly recently were considered fatal. In addition to developing drugs that boost the immune system's cancer-fighting abilities, scientists are becoming expert at manipulating ...

Anti-malaria drugs have shown promise in treating cancer, and now researchers know why

November 15, 2018
Anti-malaria drugs known as chloroquines have been repurposed to treat cancer for decades, but until now no one knew exactly what the chloroquines were targeting when they attack a tumor. Now, researchers from the Abramson ...

Standard chemotherapy treatment for HPV-positive throat cancer remains the most effective, study finds

November 15, 2018
A new study funded by Cancer Research UK and led by the University of Birmingham has found that the standard chemotherapy used to treat a specific type of throat cancer remains the most effective.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.